Podcast

Why Does Schizophrenia Appear in Young Adults?

Recent research explores the effects of a schizophrenia risk factor (DISC1) and its influence over the onset of the disease.

Click here to download and listen to this podcst.

Schizophrenia typically shows up in young adults. For men it tends to emerge around 20 to 28 years and peak onset for women is between 26 to 32 years. But what triggers the disease during this time?

Well past studies have shown that mutations in a gene called DISC1 are linked to schizophrenia. DISC1 enables a guide to new nerve cells—sort of like a traffic cop—sending them to the right place to make the right connections to other cells.

But recently, researchers partially shut off DISC1 in lab mice to see what happens when there is no traffic cop. And what they saw is a steady decrease in the size and number of dendritic spines, the tiny branches of the nerve cell that receive messages from nearby cells. Their results are published in the March issue of Nature Neuroscience.

Connections between cells are constantly broken and forged throughout our lives but there’s an amazingly large amount of so-called “pruning” during adolescence. So if this breaking of connections goes awry, as it does when DISC1 is shut off, then one might be at high risk for schizophrenia.

And so while the defective gene may be there at birth, its effect does not show up until many years into one’s life, post adolescence in young adulthood.

Source: Scientific American

Related Videos
Parent Stress Reduces Over Time When Weaning Child Off Tube Feeding with Hide Okuno, MS
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
Diabetes Dialogue: Latest Updates on Semaglutide Shortage, Data | Image Credit: HCPLive
Physician, Patient, and Partner Perspectives on AERD with Mitchell Grayson, MD, Rhonda Nelson, and Wayne Nelson
Akif Shameem, MD: Generalized Anxiety Disorder Linked to Longer Hospitals in Children with IBD
How Artificial Intelligence is Being Used in Lung Imaging, with Rachel Eddy, PhD
Jonathan Meyer, MD: Cognitive Gains, Dopamine-Free Schizophrenia Treatment with Xanomeline Trospium Chloride
Chelsie Monroe: Challenges Clinicians Should Consider When Prescribing Muscarinic Modulators for Schizophrenia
© 2024 MJH Life Sciences

All rights reserved.